These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34389461)

  • 21. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant.
    Modesto W; Dal Ava N; Monteiro I; Bahamondes L
    Arch Gynecol Obstet; 2015 Dec; 292(6):1387-91. PubMed ID: 26088190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
    Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
    Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levonorgestrel intrauterine device use and incident idiopathic intracranial hypertension among commercially insured women.
    De Lott LB; Moniz MH; Niziol LM; Khanna S; Musch DC; Cornblath WT
    Contraception; 2023 Sep; 125():110089. PubMed ID: 37331461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obstetrician-gynecologists and contraception: long-acting reversible contraception practices and education.
    Luchowski AT; Anderson BL; Power ML; Raglan GB; Espey E; Schulkin J
    Contraception; 2014 Jun; 89(6):578-83. PubMed ID: 24656553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties.
    Luukkainen T; Toivonen J
    Contraception; 1995 Nov; 52(5):269-76. PubMed ID: 8585882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immediate Versus Delayed Insertion of the Levonorgestrel Intrauterine Device in Postpartum Adolescents: A Randomized Pilot Study.
    Soon R; McGuire K; Salcedo J; Kaneshiro B
    Hawaii J Med Public Health; 2018 Mar; 77(3):60-65. PubMed ID: 29541551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
    Agostini A; Godard C; Laurendeau C; Benmahmoud Zoubir A; Lafuma A; Lévy-Bachelot L; Gourmelen J; Linet T
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):421-426. PubMed ID: 30499732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study of long-acting reversible contraceptive use in a UK primary care database: validation of methodology.
    Cea Soriano L; Wallander MA; Andersson SW; Requena G; García-Rodríguez LA
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):22-8. PubMed ID: 24229345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long acting reversible contraception in adolescents with cardiovascular conditions.
    Amies Oelschlager AM; Micks EA; Debiec KE; Nizamic T; Mantrala MD; Prager SW
    J Pediatr Adolesc Gynecol; 2014 Dec; 27(6):353-5. PubMed ID: 25256877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and predictors of initiation of intrauterine devices and subdermal implants immediately after surgical abortion.
    Roe AH; Fortin J; Janiak E; Maurer R; Goldberg AB
    Contraception; 2019 Aug; 100(2):89-95. PubMed ID: 31082394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):274-9. PubMed ID: 25601352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices.
    Sivin I; Stern J; Diaz J; Diaz MM; Faundes A; el Mahgoub S; Diaz S; Pavez M; Coutinho E; Mattos CE
    Contraception; 1987 Mar; 35(3):245-55. PubMed ID: 3111785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in uptake and cost of long-acting reversible contraceptive devices following the introduction of a new low-cost levonorgestrel IUD in Utah's Title X clinics: a retrospective review.
    Roth LP; Sanders JN; Simmons RG; Bullock H; Jacobson E; Turok DK
    Contraception; 2018 Jul; 98(1):63-68. PubMed ID: 29574095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of short-term bleeding and cramping patterns with long-acting reversible contraceptive method satisfaction.
    Diedrich JT; Desai S; Zhao Q; Secura G; Madden T; Peipert JF
    Am J Obstet Gynecol; 2015 Jan; 212(1):50.e1-8. PubMed ID: 25046805
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I; Bosman S; Beksinska M; Scoville CW; Smit J; Nanda K
    Contraception; 2022 Apr; 108():37-43. PubMed ID: 34848180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.